Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Food and Drug Administration (FDA) has approved Pacira Pharmaceuticals' Exparel for post surgical pain management.
Subscribe to our email newsletter
Exparel is a multivesicular liposomal combined therapy product including bupivacaine with a delivery technology – DepoFoam.
Exparel with DepoFoam delivers bupivacaine for an extended period of time, providing analgesia for up to 72 hours.
University of California surgery associate professor Sonia Ramamoorthy said Exparel, a single dose administration, non-opioid therapy, has the potential to reduce or delay the use of opioids following inpatient and outpatient surgical procedures.